Abstract
Crohn's disease (CD) is a chronic inflammatory disorder characterized by focal, asymmetric, transmural inflammation of any part of the luminal gastrointestinal tract of uncertain etiology and an unpredictable course. The available treatment options include aminosalicylates, budesonide and systemic corticosteroids, antibiotics, immunomodulators,methotrexate and anti-TNF agents. This review discusses recent developments in the treatment of CD and provides a comprehensive update on management of patients with CD based on the data from randomized controlled trials.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Anti-Inflammatory Agents / therapeutic use*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Budesonide / therapeutic use*
-
Crohn Disease / drug therapy*
-
Humans
-
Immunologic Factors / therapeutic use*
-
Immunosuppressive Agents / therapeutic use
-
Mesalamine / therapeutic use
-
Methotrexate / therapeutic use
-
Natalizumab
-
Sulfasalazine / therapeutic use
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal, Humanized
-
Immunologic Factors
-
Immunosuppressive Agents
-
Natalizumab
-
Tumor Necrosis Factor-alpha
-
Sulfasalazine
-
Mesalamine
-
Budesonide
-
Methotrexate